Join the new working group on in silico applications

This Avicenna Alliance working group aims to deploy in silico methods downstream and design comprehensive solutions (process, access to research, software, hardware, humanware, possibly services) to allow any organization to time and cost effectively adopt and deploy in silico methods all along the development, registration and life cycle of the products.

Are you a VPHi member? Join this new Avicenna Alliance working group led by by Cecile Rousseau, PhD (VCLS) and Emmanuelle Voisin, PhD (VCLS).

Digital evidence can and must be used for regulatory approval in all parts of the world. The Research & Technology Working Group has made huge progress, which now allows to start applying modeling and simulation, as properly defined, to accelerate medical innovation access to patients.

Many organizations are willing to invest in in silico but practical implementation guidance is needed:

  • How can I scale up my pharmaceutical process to produce medicine for the next approval phase?
  • How can I actually bring in silico to the hospital daily activities and the patients?
  • How can I deploy in silico methods as part of my regulatory approval process?

The key goals of this group are:

  • Deploy in silico methods to optimize and streamline product quality and manufacturing through the product life-cycle.

  • Regulatory: Identify and address the challenge to deploy Computer Modelling and Simulation & Artificial Intelligence to refine, reduce or replace animal studies and clinical trials.

  • Promote and implement in silico medicine in healthcare, including clinical diagnostics (e.g., clinical decision support tool and AI-powered pathology), โ€œproactiveโ€ vigilance.

  • Engage with reimbursement entities to understand, recognize and request the integration of in silico methods for healthcare

Priorities 2023 - 2024 and beyond:


  • Demonstrate added value of in silico approaches in CMC: from early stage (tech transfer) up to post-market (lifecycle);
  • Evaluate the use of in silico approaches in nonclinical development;
  • Assess current application of in silico approaches in clinical setting (in development and beyond).


  • Position paper(s): mapping of the current added value of in silico approaches in product life-cycle and clinical use
  • Promote implementation of in silico approaches (with R&T WG and Int. WG);
  • Educate stakedholders via position paper(s) and/or webinars.

2025 and beyond:

  • Sustain in silico advocacy for Medicinal Devices, Pharmaceuticals & other HealthTech products.

If you're interested to join please contact

Get an overview of the working groups and related task forces, by downloading this brochure

Date: 22/02/2023 | Tag: | News: 1418 of 1588
All news


More news


More events

Subscribe to the VPH Institute Newsletter


Read all the newsletters of the VPH Institute